The only drug that has ever worked particularly well at persuading smokers to put the lighter down is Chantix (varenicline), sold in the EU as Champix. At its peak, in 2019, the α4β2 nicotinic acetylcholine receptor agonist made $1.1bn for its maker, Pfizer Inc. But Chantix went generic in 2021, and last year its sales came to just $4m.
Achieve Life Sciences Believes It Has The New Chantix
Armed with an old drug and new data, the group is aiming to revitalize the smoking cessation market.
